Dosing Regimen for a Selective S1P1 Receptor Agonist
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/IB2009/051030, filed Mar 12, 2009. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,251,867 | Dosing Regimen for a Selective S1P1 Receptor Agonist In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | ||
| US 10,660,880 | Dosing Regimen for a Selective S1P1 Agonist In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | ||
| US 8,785,484 | Dosing Regimen for a Selective S1P1 Receptor Agonist In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | ||
| Application 14/308,598 | Dosing Regimen for a Selective S1P1 Receptor Agonist Abandoned Abandoned Sep 21, 2021 | Actelion Pharmaceuticals Ltd. | Abandoned | Abandoned Sep 21, 2021 | ||
| Application 14/322,801 | Dosing Regimen for a Selective S1P1 Receptor Agonist Abandoned Abandoned Oct 20, 2016 | Actelion Pharmaceuticals Ltd. | Abandoned | Abandoned Oct 20, 2016 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Actelion Pharmaceuticals Ltd.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.